Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.3)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 7, July, p. 941–945

doi: 10.17219/acem/70745

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Differential altered expression of let-7a and miR-205 tumor-suppressor miRNAs in different subtypes of breast cancer under treatment with Taxol

Faezeh Asghari1,2,A,B,C,D, Navideh Haghnavaz1,A,B, Darioush Shanehbandi1,B,C, Vahid Khaze1,C, Behzad Baradaran1,A, Tohid Kazemi1,A,B,E,F

1 Immunology Research Center, Tabriz University of Medical Sciences, Iran

2 Student Research Committee, Tabriz University of Medical Sciences, Iran

Abstract

Background. MicroRNAs (miRNAs) are small non-coding RNAs which have been considered as major players in the process of carcinogenesis and drug responsiveness of breast cancer.
Objectives. In this study, we aimed to investigate the expression pattern of let-7a and miR-205 tumorsuppressor miRNAs in breast cancer cell lines under treatment with paclitaxel.
Material and Methods. The half maximal inhibitory concentration (IC50) of paclitaxel was determined for 4 breast cancer cell lines, including MCF-7, MDA-MB-231, SKBR-3, and BT-474 by an MTT assay. The expression level of let-7a and miR-205, and their targets, K-RAS and HER3, was determined before and after treatment with paclitaxel, using quantitative reverse transcriptase real-time polymerase chain reaction (qRT-PCR).
Results. After treatment, the expression level of both let-7a and miR-205 was significantly increased in HER2- overexpressing cell line BT-474 (26.4- and 7.2-fold, respectively). In contrast, the HER2-negative cell lines MCF-7 and MDA-MB-231 showed a significantly decreased expression of both let-7a (30.3- and 13.5-fold, respectively) and miR-205 (20- and 18.1-fold, respectively). Controversially, SKBR-3 revealed a significantly decreased expression of both let-7a (1.3-fold) and miR-205 (1.3-fold). The expression level of K-RAS as a target of let-7a decreased in all cell lines significantly, but the pattern of alteration in the expression level of HER3 as a target of miR-205 in all cell lines was the reverse of the pattern of alteration in the expression level of miR-205.
Conclusion. Our results confirmed a better response of HER2-overexpressing breast cancer to paclitaxel at the miRNA level. One putative reason could be the upregulation of tumor-suppressor miRNAs after treatment with paclitaxel. On the other hand, HER2-negative breast cancer cell lines showed a significantly decreased expression of tumor-suppressor miRNAs, a putative mechanism of resisting the therapy.

Key words

breast cancer, microRNA, tumor-suppressor, Taxol

References (33)

  1. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol. 2011;223(2):308–318.
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
  3. Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P, Starosławska E. Breast cancer risk factors. Prz Menopauz. 2015;14(3):196.
  4. Ford D, Easton D, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62(3):676–689.
  5. Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993;53(20):4960–4970.
  6. Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: Mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 2012; 33(11):2007–2017.
  7. Nelson HD, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to 49 years: A systematic review and meta-analysis. Ann Intern Med. 2012;156(9):635–648.
  8. Polyak K. Heterogeneity in breast cancer. J Clin Invest. 2011;121(10): 3786.
  9. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: A pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250–263.
  10. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–271.
  11. Patt D, Gauthier M, Giordano S. Paclitaxel in breast cancer. Womens Health (Lond). 2006;2(1):11–21.
  12. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012;6(6): 590–610.
  13. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: Approaches and considerations. Nat Rev Genet. 2012;13(5):358–369.
  14. Iorio MV, Ferracin M, Liu C-G, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–7070.
  15. Kent O, Mendell J. A small piece in the cancer puzzle: MicroRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25(46):6188–6196.
  16. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol. 2008; 18(10):505–516.
  17. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120(5):635–647.
  18. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007;315 (5818):1576–1579.
  19. Asghari F, Haghnavaz N, Baradaran B, Hemmatzadeh M, Kazemi T. Tumor suppressor microRNAs: Targeted molecules and signaling pathways in breast cancer. Biomed Pharmacother. 2016;81:305–317.
  20. Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, et al. Micro (mi) RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle. 2011;10(7):1144–1151.
  21. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109–1123.
  22. Shingara J, Keiger K, Shelton J, et al. An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA. 2005; 11(9):1461–1470.
  23. Wu H, Zhu S, Mo Y-Y. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 2009;19(4):439–448.
  24. Kazemi T, Asgarian-Omran H, Memarian A, et al. Low representation of Fc receptor-like 1–5 molecules in leukemic cells from Iranian patients with acute lymphoblastic leukemia. Cancer Immunol Immunother. 2009;58(6):989–996.
  25. Hemmatzadeh M, Mohammadi H, Karimi M, Musavishenas MH, Baradaran B. Differential role of microRNAs in the pathogenesis and treatment of esophageal cancer. Biomed Pharmacother. 2016;82:509–519.
  26. Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 2008;7(7):2152–2159.
  27. Ichikawa T, Sato F, Terasawa K, et al. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PLoS ONE. 2012;7(2):e31422.
  28. Shah MY, Pan X, Fix LN, Farwell MA, Zhang B. 5‐fluorouracil drug alters the microRNA expression profiles in MCF‐7 breast cancer cells. J Cell Physiol. 2011;226(7):1868–1878.
  29. Rossi L, Bonmassar E, Faraoni I. Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res. 2007;56(3):248–253.
  30. Konecny GE, Thomssen C, Lück HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst. 2004;96(15):1141–1151.
  31. Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007;357(15):1496–1506.
  32. Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2008;358(2):197.
  33. Thissen JA, Gross JM, Subramanian K, Meyer T, Casey PJ. Prenylation-dependent association of Ki-Ras with microtubules: Evidence for a role in subcellular trafficking. J Biol Chem. 1997;272(48):30362–30370.
© Wroclaw Medical University